Pituitary mass with cerebrospinal fluid seeding: A rare presentation of probable pituitary carcinoma: A case report.
DOI:
https://doi.org/10.51168/j831fe35Keywords:
Pituitary carcinoma, adolescent, cerebrospinal fluid dissemination, MRI, temozolomide, aggressive pituitary tumorAbstract
Introduction:
Pituitary carcinomas (PCs) are exceptionally rare neoplasms (0.1–0.2% of pituitary tumors), defined by metastatic spread and typically diagnosed in older adults. Presentation in adolescence is extraordinarily uncommon, and radiological evidence of cerebrospinal fluid (CSF) dissemination before histopathological confirmation is even rarer.
Case Presentation:
This case report discusses a 15-year-old female with hyperprolactinemia and progressive visual blurring. Contrast-enhanced MRI revealed a large (35 × 17 × 20 mm) hour-glass-shaped sellar mass with suprasellar extension, bilateral internal carotid artery encasement, and multiple enhancing nodular deposits in the ambient cisterns, findings consistent with a locally aggressive pituitary neoplasm and probable CSF dissemination.
Conclusion:
This case illustrates that pituitary carcinoma, though rare, should be considered in adolescents when MRI demonstrates aggressive features such as arterial encasement and leptomeningeal nodules. Early recognition of these imaging red flags is critical to expedite histopathological diagnosis and initiate multidisciplinary management.
Take Away Lessons:
(i) Hour-glass morphology and carotid encasement in a pediatric pituitary mass warrant suspicion for malignancy; (ii) Nodular CSF deposits in the ambient cisterns are highly suggestive of metastatic dissemination; (iii) MRI provides non-invasive clues that can guide timely biopsy and targeted therapy; (iv) Multidisplinary approach including counselling is required to thwart and or demisify cultral beliefs that may be a barrier to early diagnosis and treatment.
References
1. Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB. Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary. 2018 Jun 5;21(3):290-301. https://doi.org/10.1007/s11102-018-0872-8
2. Du P, Wu X, Lv K, Xiong J, Geng D. A Pituitary Carcinoma Patient With Cerebrospinal Fluid Dissemination Showing a Good Response to Temozolomide Combined With Whole-Brain and Spinal Cord Radiotherapy: A Case Report and Literature Review. Front Oncol. 2022 Jul 12;12. https://doi.org/10.3389/fonc.2022.890458
3. Xu L, Khaddour K, Chen J, Rich KM, Perrin RJ, Campian JL. Pituitary carcinoma: Two case reports and review of literature. World J Clin Oncol. 2020 Feb 24;11(2):91-102. https://doi.org/10.5306/wjco.v11.i2.91
4. Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Dekkers O, Popovic V, Wierinckx A, et al. Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinicians' questions. Rev Endocr Metab Disord. 2020 Jun 5;21(2):243-51. https://doi.org/10.1007/s11154-020-09562-9
5. Melmed S. Pituitary-Tumor Endocrinopathies. New England Journal of Medicine. 2020 Mar 5;382(10):937-50. https://doi.org/10.1056/NEJMra1810772
6. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017 Oct 18;134(4):521-35. https://doi.org/10.1007/s00401-017-1769-8
7. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018 Jan;178(1): G1-24. https://doi.org/10.1530/EJE-17-0796
8. McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018 Mar;178(3):265-76. https://doi.org/10.1530/endoabs.49.OC12.2
9. Kontogeorgos G, Thodou E, Koutourousiou M, Kaltsas G, Seretis A. MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications. Pituitary. 2019 Dec 30;22(6):614-9. https://doi.org/10.1007/s11102-019-00993-5
10. Pinchot SN, Sippel R, Chen H. ACTH-producing carcinoma of the pituitary with refractory Cushing's Disease and hepatic metastases: a case report and review of the literature. World J Surg Oncol. 2009 Dec 8;7(1):39. https://doi.org/10.1186/1477-7819-7-39
11. Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, et al. Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide. J Clin Endocrinol Metab. 2015 Apr;100(4):1689-98.
https://doi.org/10.1210/jc.2014-4350
12. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017 Sep 1;28(3):228-43. https://doi.org/10.1007/s12022-017-9498-z
Downloads
Published
Issue
Section
License
Copyright (c) 2026 AMPURIIRE NYAKUBAHO, (M.D.), KAWOOYA G MICHAEL (Prof) (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
